finding delphi in medical imaging - fondation the ark · 2015. 6. 12. · •prophylactic...

70
Finding Delphi in Medical Imaging Eldad Elnekave, MD Chief Medical Officer Zebra Medical Vision

Upload: others

Post on 19-Feb-2021

0 views

Category:

Documents


0 download

TRANSCRIPT

  • Finding Delphi in Medical

    Imaging

    Eldad Elnekave, MD

    Chief Medical Officer

    Zebra Medical Vision

  • 1948

  • “Because coronary heart disease is often manifested as sudden unexpected death… a preventative program is necessary”

    -William B Kannel, MD, MPH

    Who will die of CHD?

    How can we change the course of a person’s future?

  • 1948 Hypotheses on CVD

    • Blood pressure? • Serum cholesterol levels? • Tobacco smoking? • Occasional alcohol intake? • Thyroid function? • Hemoglobin levels? • Body weight? • Diabetes? • Gout?

  • • 50 years (1950-1999)

    • 811 Cardiac Deaths

    • 400+ publications

    • “The risk of Sudden Cardiac Death and nonsudden Coronary Heart Disease mortality have decreased by 49% to 64% over the past 50 years.”

  • Finding Delphi in Medical Imaging

    600 BC – 400 AD 1948 2015

  • Big Data beginning to impact healthcare

  • Detrano et al., NEJM 2008

  • title

    Wells et al., NEJM 2012

  • title

    Pickhardtet al., Ann Int Med2013

  • “Predictive Analytics” & Finding Insight in the Voxels

    • Which lung nodules are benign and which are malignant?

    • Which heart failure patients are at highest risk for repeat exacerbations?

    • Which COPD patients will respond best to steroids and who to antibiotics?

    • Which colon cancers are surgically curable?

    • Who is at highest risk for osteoporotic fractures and will benefit from prophylaxis?

  • We know the answers are there, in the voxels…

  • The Challenge: Extracting Insights Using Medical Imaging Algorithms

    • Why? – The pace of radiology examinations is far outgrowing the

    supply of radiologists – Even trained radiologists are often unable to decipher

    imaging patterns detectable via machine learning

    • How? – Creating the worlds largest indexed and annotated imaging

    database – Allowing open access & collaborative space for

    multidiscipline research teams and clinicians – Creating a regulatory pipeline and distribution channel to

    bring innovations to real-world practice

  • Silos of Medical Imaging Datasets Limits Innovation and Validation

  • Public radiology databases remain relatively small & disease - modality specific

    Tera

    byt

    es

    Sto

    red

  • Zebra launches the worlds largest database of de-identified, longitudinal medical imaging

    Tera

    byt

    es

    Sto

    red

  • • ImageNet Large Scale

    Visual Recognition Challenge 2014: • 38 Entrants from 13

    Countries • Training: 456,567 Images •Validation: 20,121 Images

  • ###,###,###

  • ###,###,###

  • Talent-Silos Impede the Pace of Breakthrough Discoveries

  • Talent-Silos Impede the Pace of Breakthrough Discoveries

  • Talent-Silos Impede the Pace of Breakthrough Discoveries

  • Image Process Segmentation Registration

    Transformation

    Quantitative imaging

    Unsupervised ML

    Radiomics

    Texture analysis

    Semantic

  • Image Process Segmentation Registration

    Transformation

    Unsupervised ML

    Radiomics

    Clinical Rad

    visualiz-ation

    Semantic

    Quantitative imaging Texture analysis

  • “Indication: Lung Cancer Screening”

    1. No Acute Findings 2. Emphysema and coronary calcium

    noted 3. 5mm x 6mm RUL nodule, 5mm x

    4mm LLL nodule; recommend follow up exam in 6-12 months to assess for change.

  • “Indication: Lung Cancer Screening”

    1. No Acute Findings 2. Emphysema and coronary calcium

    noted 3. 5mm x 6mm RUL nodule, 5mm x

    4mm LLL nodule; recommend follow up exam in 6-12 months to assess for change.

    1. RUL Nodule Feature Characterization = 98.6% Malignant

    2. LLL Nodule Feature Assessment: 90% Benign Post Inflammatory

    3. Left Adrenal Nodule Feature Characterization: 99.99% Benign Adenoma

    4. Coronary risk stratification: 8.4 5. Lung parenchymal changes since

    23 months prior: Overall 8.3 +6% 1. Bronchiectasis: 7.2, +12% 2. Emphysema 8.8, +9% 3. Bronchial wall thickening:

    6.0 +2%

    6. Osteoporotic risk score: -2.3 1. BMD: -2.0 2. Cortical thickness: 4 3. Medullary uniformity: 6 4. Trabecular thickness

    7. Metabolic assessment: 7.33 1. Intra-abdominal fat 2. Liver Density

    8. Cardiac chamber biometrics: 12.4 1. LV Thickness 2. Total Volume

  • The Radiologist, 1990

  • The Radiologist, 2015

    !

  • The Zebra- Backed Radiologist (the Zebradiologist)

  • Thanks ;)

    Questions?

    [email protected]

    Zebra//

    is the medical slang for arriving at an exotic

    medical diagnosis when a more

    commonplace explanation is more likely.

  • “Indication: Lung Cancer Screening”

    1. No Acute Findings 2. Emphysema and coronary calcium

    noted 3. 5mm x 6mm RUL nodule, 5mm x

    4mm LLL nodule; recommend follow up exam in 6-12 months to assess for change.

  • “Indication: Lung Cancer Screening”

    1. No Acute Findings 2. Emphysema and coronary calcium

    noted 3. 5mm x 6mm RUL nodule, 5mm x

    4mm LLL nodule; recommend follow up exam in 6-12 months to assess for change.

  • “Indication: Lung Cancer Screening”

    1. No Acute Findings 2. Emphysema and coronary calcium

    noted 3. 5mm x 6mm RUL nodule, 5mm x

    4mm LLL nodule; recommend follow up exam in 6-12 months to assess for change.

  • “Indication: Lung Cancer Screening”

    1. No Acute Findings 2. Emphysema and coronary calcium

    noted 3. 5mm x 6mm RUL nodule, 5mm x

    4mm LLL nodule; recommend follow up exam in 6-12 months to assess for change.

    1. RUL Nodule Feature Characterization = 98.6% Malignant

    2. LLL Nodule Feature Assessment: 90% Benign Post Inflammatory

    3. Left Adrenal Nodule Feature Characterization: 99.99% Benign Adenoma

    4. Coronary risk stratification: 8.4 5. Lung parenchymal changes since

    23 months prior: Overall 8.3 +6% 1. Bronchiectasis: 7.2, +12% 2. Emphysema 8.8, +9% 3. Bronchial wall thickening:

    6.0 +2%

    6. Osteoporotic risk score: -2.3 1. BMD: -2.0 2. Cortical thickness: 4 3. Medullary uniformity: 6 4. Trabecular thickness

    7. Metabolic assessment: 7.33 1. Intra-abdominal fat 2. Liver Density

    8. Cardiac chamber biometrics: 12.4 1. LV Thickness 2. Total Volume

  • Tourette

    Hepatocellular Carcinoma Lymphoma Cholangiocarcinoma

    Addisons ALS Beckwith-Wiedemann

    Behcets

    Pancreatic Adenocarcinoma Leukemia

    Burkitt Lymphoma Craniofacial Dysostosis

    Cushings

    Osteomyelitis Osteoarthritis Coronary Artery Disease

    DiGeorge Ebsteins Gardners Sturge-Weber

    Peutz-Jeghers

    Sarcoma Diabetes Colon Cancer Breast Cancer

    Zollinger-Ellison Lesch-Nyhan Hirschsprung

    Moyamoya

    Rheumatoid Arthritis Aortic stenosis

    Wegener Granulomatosis

    Tolosa-Hunt

    Wolff-Parkinson-White

    Multiple Sclerosis Osteoporosis

    Stroke

    Hepatolenticular Degeneration

    Hodgkins Lymphoma

    Emphysema Non-small Cell Lung Cancer

    Islet Cell Tumors

  • Tourette

    Hepatocellular Carcinoma Lymphoma Cholangiocarcinoma

    Addisons ALS Beckwith-Wiedemann

    Behcets

    Pancreatic Adenocarcinoma Leukemia

    Burkitt Lymphoma Craniofacial Dysostosis

    Cushings

    Osteomyelitis Osteoarthritis Coronary Artery Disease

    DiGeorge Ebsteins Gardners Sturge-Weber

    Peutz-Jeghers

    Sarcoma Diabetes Colon Cancer Breast Cancer

    Zollinger-Ellison Lesch-Nyhan Hirschsprung

    Moyamoya

    Rheumatoid Arthritis Aortic stenosis

    Wegener Granulomatosis

    Tolosa-Hunt

    Wolff-Parkinson-White

    Multiple Sclerosis Osteoporosis

    Stroke

    Hepatolenticular Degeneration

    Hodgkins Lymphoma

    Emphysema Non-small Cell Lung Cancer

    Islet Cell Tumors

  • Tourette

    Hepatocellular Carcinoma Lymphoma Cholangiocarcinoma

    Addisons ALS Beckwith-Wiedemann

    Behcets

    Pancreatic Adenocarcinoma Leukemia

    Burkitt Lymphoma Craniofacial Dysostosis

    Cushings

    Osteomyelitis Osteoarthritis Coronary Artery Disease

    DiGeorge Ebsteins Gardners Sturge-Weber

    Peutz-Jeghers

    Sarcoma Diabetes Colon Cancer Breast Cancer

    Zollinger-Ellison Lesch-Nyhan Hirschsprung

    Moyamoya

    Rheumatoid Arthritis Aortic stenosis

    Wegener Granulomatosis

    Tolosa-Hunt

    Wolff-Parkinson-White

    Multiple Sclerosis Osteoporosis

    Stroke

    Hepatolenticular Degeneration

    Hodgkins Lymphoma

    Emphysema Non-small Cell Lung Cancer

    Islet Cell Tumors

  • Results

    • Subjects in the highest risk category had an almost six-fold risk of coronary artery events compared with those without detectable CAC.

    • “Approximately 55% of study participants with intermediate to high risk and 43% of participants with very high risk of CVD events do not receive optimal treatment of CVD risk factors (antihypertensives or statins) – “Around 50% of these subjects actually had elevated BP or

    lipids… all are likely to benefit from risk factor treatment because of their high CAC score alone…”

    • In 1000 participants without a history of CHD, one would detect 175 subjects with a massively increased risk basee don CAC >1000 and of these, 84 subjects could benefit from starting preventative medical treatment.

  • • >1 million Osteoporosis-related fractures occur each year in the US alone.

    • Prophylactic bisphosphonate treatment can reduce fracture risk by ~50% in osteoporotic individuals

    • DEXA is the standard screening examination but it is severely underutilized:

    • Fewer than 20% of fractures occur in people who have undergone DEXA and are under prophylaxis treatment.

    • >100 million CT studies are performed in the US annually • Could CT scans obtained for whatever clinical indication be

    used to assess bone mineral density and fracture risk? • 1867 Patients with CT and DEXA obtained within 6 months

    from one another were assessed

    Pickhart et al, Annals Internal Med 2013

  • Pickhart et al, Annals Internal Med 2013

  • Results

    • An L1 CT-attenuation threshold of 160 HU or less was 90% sensitive and a threshold of 110 HU was more than 90% specific for distinguishing osteoporosis from osteopenia and normal BMD.

    • Among 119 patients with at least 1 moderate-to-severe vertebral fracture, 62 (52.1%) had nonosteoporotic T-scores (DXA false-negative results), and most (97%) had L1 or mean T12 to L5 vertebral attenuation of 145 HU or less.

    • Abdominal CT images obtained for other reasons that include the lumbar spine can be used to identify patients with osteoporosis or normal BMD without additional radiation exposure or cost.

  • • 1019 Patients with NSCLC or SCC

    • 440 CT features • “Radiomics identifies a

    general prognostic phenotype existing in both lung and head-and-neck cancer. This may provide an uprecedented opportunity to improve decision-support in cancer treatment at low cost.”

  • Results

    “Texture parameters derived from CT images of NSCLC have the potential to act as imaging correlates for tumor hypoxia and angiogenesis”

  • CT Texure of Primary Colorectal Cancer predicts 5 year survival

    • 140,000 people are diagnosed with colon cancer every year in the US.

    • Of those who undergo surgery, (approximately 100,000) 30% will develop recurrence, usually within 3 years. Median time from recurrence to death is 12 months and most of these patients will recur with liver metastases.

    • At present we have no way to predict which tumors have already released metastatic cells at the time of surgery. Current guidelines rely upon TNM staging to determine surgical and chemotherapy management, but can we improve?

    Goh et al, Radiology 2014

  • “Texture analysis of primary colorectal cancers were predictive of 5-year survival as good as, and independent of, tumor staging. If this were validated, we might be able to change surveillance or even proactively treat at risk patients following surgical resection.”